pfizer.com - PFE Enterprise Value to Sales Volume

Public company logo of Pfizer (PFE)

Pfizer Inc. (PFE) is scaling its business through the acquisition of biotech corporations and strategic alliances. Global partnerships with institutions are accelerating vaccine development and clinical trials. However, declining revenues and patent expirations are weakening its market position. The enterprise value-to-revenue multiple helps identify macro risks within a sideways trend, with the current figure standing at 3279.15.

PFE Pfizer Inc: Company Value to Revenue in the range 11/23/2025 - 11/19/2026

PFE (Pfizer Corporation): analytical breakdowns and indicator data

- stock quotes and analyst forecast:
Fundamental valuation:Pfizer Inc. PFE
Core merchandise of Pfizer Inc

This indicator serves as an asset stress-testing tool, allowing for the identification of overvaluation relative to actual cash flows. The metric compares the total enterprise value to annual turnover, neutralizing the impact of debt load to determine the fundamental value of one dollar of revenue. The rise in the enterprise value-to-revenue multiple amid underutilized capacity at Pfizer Inc. (PFE) signals speculative optimism, which conflicts with the company's current increase in unit costs.